Primary PCI with Bioresorbable Vascular Scaffolds

Original Title: One-year Clinical and Computed Tomography Angiographic Outcomes after Bioresorbable Vascular Scaffold Implantation during Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. The Prague-19 Study. Reference: Widimsky P et al. Circ Cardiovasc Interv. 2015 Dec;8(12).

Courtesy of Dr. Carlos Fava.

Primary PCI is the most common course of treatment for ST elevation myocardial infarction (STEMI) but the role of bioresorbable scaffolds (BVS) in this context remains unclear.

This prospective study included 70 STEMI patients undergoing primary PCI with BVS. Three patients could not receive BVS and got a bare metal stent instead.

At 30 days, there was definite thrombosis of BVS in a patient that had stopped DAPT and one death for a mechanical complication of infarction. At one year, there was one case of restenosis and a sudden death.

After 1 year, computed tomographic angiography performed in 59 patients showed binary restenosis rate of 2% and minimal luminal diameter of 3.0±0.6 mm.

Conclusion
The use of bioresorbable scaffold in the context of STEMI is feasible and safe, and offers excellent clinical and angiographic evolution at one year.

Editorial Comment
This study shows that the use of these new devices is favorable in complex scenarios such as PCI, with the advantage of recovering vessel physiology in time. At present, BVS present certain limitations, such as the limited choice of size, apart from the need of vessel preparation before implantation.

Courtesy of Dr. Carlos Fava.
Cardiólogo Intervencionista
Fundación Favaloro – Buenos Aires

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...